Patients with Crohn's disease who become unresponsive to therapy with tumor necrosis factor antagonists are initially managed with either a test-based strategy, or an empiric dose-escalation strategy. A study in the June issue of CGH examines which strategy is more cost-effective.  Dr. Kuemmerle speaks to Dr. Fernando S. Velayos of the University of California, San Francisco; Plus, summaries of top stories from this month's issue of GI and Hepatology News.

In the last several years, many gastroesophageal reflux disease (GERD) patients have been treated with a variety of proton pump inhibitors (PPIs), while at the same time there has been a surge in surgical fundoplication to treat other GERD patients. Dr. Kuemmerle discusses the pros and cons of both approaches with authors of new articles in the May issue of CGH: Dr. David A. Johnson of Eastern Virginia Medical School, and Dr. Joel E. Richter of the University of South Florida Morsani College of Medicine; Plus, summaries of top stories from this month's issue of GI and Hepatology News.

An editorial in the April issue of CGH takes a new look at the risks and benefits of thiopurines in treating Crohn's disease. Dr. Kuemmerle speaks to Dr. Stephen B. Hanauer of the University of Chicago Medical Center

31 pregnant women with inflammatory bowel disease (IBD) who receive anti–tumor necrosis factor (TNF) agents were studied to determine whether these drugs are transferred to the fetus via the placenta and then cleared, or whether structurally different TNF antagonists have different rates of transfer. Dr. Kuemmerle speaks to Dr. Uma Mahadevan of the University of California, San Francisco, about the results, which appear in the March issue of CGH. Plus, summaries of top stories from this month's issue of GI and Hepatology News.

A study in the February issue of CGH evaluated the prevalence of adenomas detected by sex, age, race/ethnicity, and colon location in a large population. Dr. Kuemmerle discusses the implications of these findings for screening and quality programs with author Dr. Douglas Corley of Kaiser Permanente; Plus, summaries of top stories from this month's issue of GI and Hepatology News.

An “Advances in Translational Science” article in the February issue of CGH discusses how studying the effect of inflammatory bowel disease (IBD) susceptibility gene dysfunctions in tissue cultures and animal models will allow the ultimate translational benefits of developing novel treatments for and potentially preventing IBD in those having specific genetic risk factors. Dr. Kuemmerle speaks with Dr. Steven Brant of Johns Hopkins Hospital, Division of Gastroenterology.

Obscure gastrointestinal bleeding (OGIB) has remained a challenge in its diagnosis and treatment. Two studies in the December issue of CGH report factors that are associated with positive findings and diagnostic yield in investigation of OGIB using video capsule enteroscopy.  Dr. Kuemmerle speaks to the author of an editorial on these two articles, Dr. Shajan Peter of the University of Alabama at Birimingham, Alabama; Plus, summaries of top stories from this month's issue of GI and Hepatology News.

An article in the November issue of CGH offers a road map for GI practitioners who are undertaking the complex, arduous task of transitioning to electronic health records in their hospitals, offices, and ambulatory surgical centers.  Dr. Kuemmerle speaks to Dr. Michael L. Weinstein of Metropolitan Gastroenterology Group about this article in CGH's “Practice Management: The Road Ahead” section; Plus, a rundown of top stories from this month's issue of GI and Hepatology News.

An article in the October issue of CGH reviews the latest approach to diagnosis of eosinophilic esophagitis (EoE) and presents consensus diagnostic guidelines; The article also discusses the clinical, endoscopic, and histologic features of EoE and challenges to diagnosis; and also presents 3 major treatment options. Dr. Kuemmerle speaks to the author of this “Perspectives in Clinical Gastroenterology and Hepatology” article, Dr. Evan S. Dellon of the University of North Carolina School of Medicine, Chapel Hill; Plus, summaries of top stories from this month's issue of GI and Hepatology News

A “Perspectives in Clinical Gastroenterology and Hepatology” article in the September issue of CGH provides condition-specific rationale for using probiotic therapy and literature-based recommendations. Dr. Kuemmerle speaks to author Dr. Matthew A. Ciorba of Washington University School of Medicine in St. Louis; Plus, summaries of top stories from this month's issue of GI and Hepatology News.